Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia

• Main Authors: Cheng-Yi Wang (Author), Chia-Hung Chen (Author), Chih-Yen Tu (Author), Wei-Chih Chen (Author), Li-Kuo Kuo (Author), Yao-Tung Wang (Author), Pin-Kuei Fu (Author), Shih-Chi Ku (Author), Wen-Feng Fang (Author), Chin-Ming Chen (Author), Chih-Cheng Lai (Author)
• Format: Book
• Published: Elsevier, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Further...